Cargando…

DCE-MRI for Early Prediction of Response in Hepatocellular Carcinoma after TACE and Sorafenib Therapy: A Pilot Study

OBJECTIVE: Dynamic contrast-enhanced MRI (DCE-MRI) can measure the changes in tumor blood flow, vascular permeability and interstitial and intravascular volume. The objective was to evaluate the efficacy of DCE-MRI in prediction of Barcelona Clinic Liver Cancer (BCLC) staging B or C hepatocellular c...

Descripción completa

Detalles Bibliográficos
Autores principales: Saito, Kazuhiro, Ledsam, Joseph, Sugimoto, Katsutoshi, Sourbron, Steven, Araki, Yoichi, Tokuuye, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ubiquity Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032464/
https://www.ncbi.nlm.nih.gov/pubmed/30039052
http://dx.doi.org/10.5334/jbsr.1278
_version_ 1783337508163026944
author Saito, Kazuhiro
Ledsam, Joseph
Sugimoto, Katsutoshi
Sourbron, Steven
Araki, Yoichi
Tokuuye, Koichi
author_facet Saito, Kazuhiro
Ledsam, Joseph
Sugimoto, Katsutoshi
Sourbron, Steven
Araki, Yoichi
Tokuuye, Koichi
author_sort Saito, Kazuhiro
collection PubMed
description OBJECTIVE: Dynamic contrast-enhanced MRI (DCE-MRI) can measure the changes in tumor blood flow, vascular permeability and interstitial and intravascular volume. The objective was to evaluate the efficacy of DCE-MRI in prediction of Barcelona Clinic Liver Cancer (BCLC) staging B or C hepatocellular carcinoma (HCC) response after treatment with transcatheter arterial chemoembolization (TACE) followed by sorafenib therapy. METHODS: Sorafenib was administered four days after TACE of BCLC staging B or C HCC in 11 patients (21 lesions). DCE-MRI was performed with Gd-EOB-DTPA contrast before TACE and three and 10 days after TACE. DCE-MRI acquisitions were taken pre-contrast, hepatic arterial-dominant phase and 60, 120, 180, 240, 330, 420, 510 and 600 seconds post-contrast. Distribution volume of contrast agent (DV) and transfer constant Ktrans were calculated. Patients were grouped by mRECIST after one month or more post-TACE into responders (complete response, partial response) and non-responders (stable disease, progressive disease). RESULTS: DV was reduced in responders at three and 10 days post-TACE (p = 0.008 and p = 0.008 respectively). DV fell in non-responders at three days (p = 0.025) but was not significantly changed from pre-TACE values after sorafenib. Sensitivity and specificity for DV 10 days post-TACE were 88% and 77% respectively. CONCLUSION: DV may be a useful biomarker for early prediction of therapeutic outcome in intermediate HCC.
format Online
Article
Text
id pubmed-6032464
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Ubiquity Press
record_format MEDLINE/PubMed
spelling pubmed-60324642018-07-23 DCE-MRI for Early Prediction of Response in Hepatocellular Carcinoma after TACE and Sorafenib Therapy: A Pilot Study Saito, Kazuhiro Ledsam, Joseph Sugimoto, Katsutoshi Sourbron, Steven Araki, Yoichi Tokuuye, Koichi J Belg Soc Radiol Original Article OBJECTIVE: Dynamic contrast-enhanced MRI (DCE-MRI) can measure the changes in tumor blood flow, vascular permeability and interstitial and intravascular volume. The objective was to evaluate the efficacy of DCE-MRI in prediction of Barcelona Clinic Liver Cancer (BCLC) staging B or C hepatocellular carcinoma (HCC) response after treatment with transcatheter arterial chemoembolization (TACE) followed by sorafenib therapy. METHODS: Sorafenib was administered four days after TACE of BCLC staging B or C HCC in 11 patients (21 lesions). DCE-MRI was performed with Gd-EOB-DTPA contrast before TACE and three and 10 days after TACE. DCE-MRI acquisitions were taken pre-contrast, hepatic arterial-dominant phase and 60, 120, 180, 240, 330, 420, 510 and 600 seconds post-contrast. Distribution volume of contrast agent (DV) and transfer constant Ktrans were calculated. Patients were grouped by mRECIST after one month or more post-TACE into responders (complete response, partial response) and non-responders (stable disease, progressive disease). RESULTS: DV was reduced in responders at three and 10 days post-TACE (p = 0.008 and p = 0.008 respectively). DV fell in non-responders at three days (p = 0.025) but was not significantly changed from pre-TACE values after sorafenib. Sensitivity and specificity for DV 10 days post-TACE were 88% and 77% respectively. CONCLUSION: DV may be a useful biomarker for early prediction of therapeutic outcome in intermediate HCC. Ubiquity Press 2018-04-20 /pmc/articles/PMC6032464/ /pubmed/30039052 http://dx.doi.org/10.5334/jbsr.1278 Text en Copyright: © 2018 The Author(s) http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Article
Saito, Kazuhiro
Ledsam, Joseph
Sugimoto, Katsutoshi
Sourbron, Steven
Araki, Yoichi
Tokuuye, Koichi
DCE-MRI for Early Prediction of Response in Hepatocellular Carcinoma after TACE and Sorafenib Therapy: A Pilot Study
title DCE-MRI for Early Prediction of Response in Hepatocellular Carcinoma after TACE and Sorafenib Therapy: A Pilot Study
title_full DCE-MRI for Early Prediction of Response in Hepatocellular Carcinoma after TACE and Sorafenib Therapy: A Pilot Study
title_fullStr DCE-MRI for Early Prediction of Response in Hepatocellular Carcinoma after TACE and Sorafenib Therapy: A Pilot Study
title_full_unstemmed DCE-MRI for Early Prediction of Response in Hepatocellular Carcinoma after TACE and Sorafenib Therapy: A Pilot Study
title_short DCE-MRI for Early Prediction of Response in Hepatocellular Carcinoma after TACE and Sorafenib Therapy: A Pilot Study
title_sort dce-mri for early prediction of response in hepatocellular carcinoma after tace and sorafenib therapy: a pilot study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032464/
https://www.ncbi.nlm.nih.gov/pubmed/30039052
http://dx.doi.org/10.5334/jbsr.1278
work_keys_str_mv AT saitokazuhiro dcemriforearlypredictionofresponseinhepatocellularcarcinomaaftertaceandsorafenibtherapyapilotstudy
AT ledsamjoseph dcemriforearlypredictionofresponseinhepatocellularcarcinomaaftertaceandsorafenibtherapyapilotstudy
AT sugimotokatsutoshi dcemriforearlypredictionofresponseinhepatocellularcarcinomaaftertaceandsorafenibtherapyapilotstudy
AT sourbronsteven dcemriforearlypredictionofresponseinhepatocellularcarcinomaaftertaceandsorafenibtherapyapilotstudy
AT arakiyoichi dcemriforearlypredictionofresponseinhepatocellularcarcinomaaftertaceandsorafenibtherapyapilotstudy
AT tokuuyekoichi dcemriforearlypredictionofresponseinhepatocellularcarcinomaaftertaceandsorafenibtherapyapilotstudy